Hospital.Help

Standford – The risk of secondary cancer after CAR-T cell therapy is low, according to an evaluation by Stanford University. Researchers took a closer look at around 700 patients who had received CAR-T cell therapy at Stanford University Hospital since 2016. Overall, secondary hematological cancers occurred in 6.5% of cases within 3 years, write the experts in the New England…